MDMA and psilocybin psychiatric research is a bad “trip” for mental health in Australia, U.S. and globally. By CCHR International The Mental Health Industry Watchdog…
Last week, the New York Times ran a sad yet compelling story about a boy named Kyle, who at 18 months was put on antipsychotic drugs to quell severe temper tantrums. By the time he was 3, the poor kid had been diagnosed with autism, bipolar disorder, hyperactivity, insomnia and “oppositional defiant disorder” (um, isn’t that a fancy phrase for “normal toddler behavior”?). He was on the antipsychotic Risperdal, the antidepressant Prozac, two sleeping medicines and a pill for attention-deficit disorder. Did you read that?! Prozac! Sleeping pills!
AstraZeneca has agreed to settle Seroquel lawsuits filed by about 200 people who claim that the drug maker failed to adequately warn about the risk of diabetes and other side effects of their antipsychotic drug. The Seroquel settlements are reportedly the first payments AstraZeneca has made out of an estimated 26,000 claims that have been presented against the company.
Researchers found that when given to infant rats, the drugs caused behavioral abnormalities later in life. What’s more, the abnormalities were not limited to the drugs known to cause neuronal cell death. “That is of particular concern because some of the drugs may predispose to psychiatric disorders later in life,” says lead author Patrick Forcelli.